Ondine Announces Board Changes

Ondine Biomedical Inc. (LON:OBI), a Canadian life sciences company, has announced changes to its Board of Directors. Margaret Shaw has been reappointed, and Craig Tooman has resigned. Tooman, who served as Audit Committee Chair, is stepping down to focus on his role as CEO of Silence Therapeutics Inc. Shaw will chair the Audit & Risk Oversight Committee and join the Nominating & Governance Committee.

Shaw's reappointment comes as Ondine advances its photodisinfection technologies addressing healthcare-associated infections. With a career in finance, including roles at AGF Funds Inc. and CIBC, Shaw's expertise will guide the company through its next growth phase. Carolyn Cross, CEO of Ondine, expressed enthusiasm for Shaw's return, highlighting her financial acumen and strategic vision.

Tooman's contributions over the past three years were acknowledged by Cross, who wished him success at Silence Therapeutics. Shaw's appointment enhances Ondine's financial expertise, supports gender diversity, and brings strategic insight as the company seeks FDA approval and market expansion.